Sutro Announces Updated Data From Phase 1b Study Of Luvelta Combination In Epithelial Ovarian Cancer
14/9 12:06
(RTTNews) - Sutro Biopharma Inc. (STRO) announced updated data from the ongoing Phase 1b study of luveltamab tazevibulin (luvelta) in combination with bevacizumab for patients with epithelial ovarian cancer....